Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Decoy Therapeutics Inc. (DCOY)

Decoy Therapeutics: warrant inducement brings $3.85 million in gross proceeds

Mixed Impact 3 of 5 financing Written later

Decoy Therapeutics reduced the exercise price of its Series B milestone warrants from $5.91 to $3.25 per share, and the holder exercised 1,184,434 of them in full, bringing approximately $3.85 million in gross proceeds before placement agent fees and expenses; the transaction closed September 23, 2026. In exchange, the company issued new unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately and expiring five years after issuance, which could add meaningful share count dilution for existing holders.

Key points

  • 1,184,434 Series B Milestone Warrants exercised in full on September 22, 2026 at a reduced price of $3.25, down from $5.91 per share.
  • Gross proceeds of approximately $3.85 million, before placement agent fees and other expenses, to be used for working capital and general corporate purposes.
  • New unregistered warrants for up to 2,368,868 shares at $3.25 per share, exercisable immediately, expiring five years from issuance.
  • The company agreed to file a resale registration statement within 15 calendar days of the September 22, 2026 inducement letter.

The filing

CompanyDecoy Therapeutics Inc. (DCOY)
Form8-K, current report
Filed with the SECSep 23, 2026, 5:02 PM ET
Accession number0001615219-26-000019

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.